News

Evaluating pulmonary arterial hypertension patients for heart performance parameters during exercise shortly after diagnosis allows for a good indication of the chance of survival for the patient, as noted in a study published in European Respiratory…

Team PHenomenal Hope is one of the cycling teams that is set compete in a high-endurance cycling event called Race Across America (RAAM). However, their goal is not winning, but raising awareness for pulmonary hypertension (PH), a rare and debilitating lung disease that can be deadly. The race begins June,…

Bayer HealthCare recently announced it will test the efficacy and safety of the drug Riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP). The study will take place at more than 50 sites in 11 countries and will include about 120 patients. Designed…

Swiss biotech company Actelion Pharmaceuticals has launched Opsumit (macitentan) as a new treatment option for patients with pulmonary arterial hypertension (PAH) in England, where approximately 3,000 people receive disease-targeted drug therapy for the condition. This comes as significant news for Actelion, after the Institut National d’Excellence en Santé…

The Pulmonary Arterial Hypertension Foundation – Quebec (HTAPQ) expressed its disappointment with the decision made by the Institut National d’Excellence en Santé et Services Sociaux (INESSS), which didn’t include Opsumit (macitentan) on the list of medications covered by Quebec’s public drug insurance plan. Opsumit is a prescription medicine used…

Jose Caceres, MD, from Jacobi Medical Center/Albert Einstein College of Medicine, recently presented research at the 2014 American Thoracic Society International Conference that adds fuel to the “obesity paradox phenomenon.” Whereas obesity (higher body mass index, or BMI) is usually associated with poorer health outcomes, Dr. Caceres’…

Earlier in the month, Pulmonary Hypertension News Contributing Editor Charles Moore reported on how, according to Canada’s Pulmonary Hypertension Association (PHA) Patient and Caregiver Survey, those in Canada diagnosed with pulmonary hypertension (PH) are experiencing serious financial, social, and physical burdens as a result of the disease. Now, a…

It is commonly known that exercise capacity is impaired in pulmonary arterial hypertension (PAH).  Thanks to a recent study, researchers were able to test a hypothesis on why this is the case, with the idea that perhaps cardiovascular reserve anomalies are in fact linked with an impaired hemodynamics response…

Pulmonary Arterial Hypertension (PAH) is a frequently encountered complication of Systemic Sclerosis (SSc). PAH is also the leading cause of morbidity and mortality among SSc patients. Despite some progress in new detection methods, standard right heart catheterization still remains the most effective means of diagnosis of PAH with Systemic…

Drug maker Actelion has indicated that the company’s Food and Drug Administration (FDA)–approved pulmonary arterial hypertension (PAH) drug Bosentan, which is also known under the brand names of Actelion and Tracleer, recently failed a key FDA postmarket test. The test, which was part of the postmarket COMPASS 2 trial, revealed that Bosentan did not reduce time…

Pulmonary Hypertension (PH) is a rare condition characterized by increased pressure and constriction of the pulmonary arteries and the surrounding veins, which in turn applies excess pressure to the right side of the heart. It is a progressive condition that worsens with time if left untreated. The…

Rensselaer, New York-based biopharmaceutical company Pulmokine recently made a major announcement regarding the company’s efforts in developing a novel therapy for pulmonary arterial hypertension (PAH). In a press release from late March, Pulmokine indicated that that the National Heart, Lung, and Blood Institute (NHLBI), a division of the federally run National…